ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
about
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studiesAndrogen receptor and prostate cancer stem cells: biological mechanisms and clinical implicationsWhat is the Need for Prostatic Biomarkers in Prostate Cancer Management?Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypesLoss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapseOverexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate CancerFamily with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancerUsefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.SPINK1 protein expression and prostate cancer progression.Molecular pathways and targets in prostate cancerThe ETS family of oncogenic transcription factors in solid tumours.MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays.ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomyExpression of ERG protein in prostate cancer: variability and biological correlates.Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate TumorsLoss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate CancersOncogenic activation of ERG: A predominant mechanism in prostate cancer.Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionHigh-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate CancerHOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomyLessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.RNA biomarkers to facilitate the identification of aggressive prostate cancerERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients.ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer.Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisConcurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.Biomarkers in prostate cancer surveillance and screening: past, present, and future.Genetic variations of α -methylacyl-CoA racemase are associated with sporadic prostate cancer risk in ethnically homogenous Koreans.Biomarkers for prostate cancer: present challenges and future opportunities.Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.Stromal Androgen Receptor in Prostate Cancer Development and ProgressionQuality of Life and Sexual Health in the Aging of PCa Survivors.
P2860
Q24289356-E17E3E1D-5521-467D-84C5-6920ABC6EC99Q26797063-C4B1CB82-25F0-4EDE-8083-FA60E99F1B33Q26798425-9347ECB3-D192-42AF-AB2D-DED9172AC781Q27010695-F4F2100E-7C0F-4053-A7BE-115A07D37849Q28540624-1119900A-E1B4-4E68-B0F9-4D71965F7507Q28546607-2B5DC624-476D-4B6C-9DF1-35B0E46D3252Q33761801-41C526BC-191B-4B3C-8F5D-4E64FAFC7D6FQ33862890-A3CD682A-38AD-4DFC-A565-EEBBD202723DQ34036819-23227C3C-5A25-4F0A-A07B-FAA0A00BF3D4Q34203149-DF47292C-C008-4251-A221-A65A42558F90Q34365632-F7CF7B4F-0B29-485B-B0B4-9F2A3F0BB756Q34555986-8B4C198A-8472-4E25-9A13-CCF14D96E167Q34574636-A6D5C89B-4471-43CA-B30D-3C3D80E433A7Q34652823-8ACF5131-03B6-4B45-AD34-FA4C3248A5D4Q35535396-4C725CD3-62B5-4CBB-A11B-73D1A2ADCFF1Q35585704-8EE65998-87D4-4717-8B7B-B4A441303C02Q35608000-49395C79-0AA0-4D4E-9C10-5F8EAD3726F7Q35631603-55DA99BF-A05A-41D6-9B3C-DD43242A2587Q35648290-92FD89CC-E4D4-4D40-8EDA-962C8784DB84Q35685920-DECD3BD0-74F1-4DF1-87B4-BF5F007A20DAQ35690915-D070D6D3-4A7D-4451-AAED-3885DAB1D8DEQ35706611-E5AE74CA-E147-4881-82D6-593724AF6AB2Q35731092-F3AB77F3-C75E-4E06-96F9-CD79E1B0DDEBQ35828702-888336BA-17E7-4398-AA28-8D668CF2C95BQ36004694-29392974-1F9F-4DF1-BF20-D700C094F6E6Q36035812-4F403559-6513-42AF-8D1D-C59F671B761DQ36105102-A85F75F1-18E1-4A39-A8E3-72E6C8B9EE9AQ36260364-C2026BAA-14A6-4882-8C89-919BF7438FC9Q36374619-6086A757-D5AC-46BB-BA3B-0D2E76ED3983Q36741911-4ABEAB39-013B-4381-B2E0-9209A17BA771Q36848024-FE0ADD65-7B3D-4AAF-A988-3AD752979E28Q36899790-D975CB53-BCEE-44F6-837D-120B52CDBFF4Q37156611-9A949650-8685-4FC0-88D3-EF8FA623625DQ37285569-72ABD6A9-8394-4801-9078-65357E66AF85Q37300931-385855A7-58D2-4FE8-AC57-5882AE781DCAQ37409113-DAA4D376-DA34-48C2-9727-ACE18347ED9DQ37474443-9E891E91-1303-43A0-9EC2-07A4574FEA83Q37520447-43CCB68B-A495-4C9D-8D0E-F2AAB6663ECAQ37629551-3584D21D-9980-465F-84F2-04AF8EEE4457Q37686901-8CC398FF-EA6A-4A5F-A018-31CA6C2F0B8E
P2860
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
ERG status is unrelated to PSA ...... sence of antihormonal therapy.
@en
ERG status is unrelated to PSA ...... sence of antihormonal therapy.
@nl
type
label
ERG status is unrelated to PSA ...... sence of antihormonal therapy.
@en
ERG status is unrelated to PSA ...... sence of antihormonal therapy.
@nl
prefLabel
ERG status is unrelated to PSA ...... sence of antihormonal therapy.
@en
ERG status is unrelated to PSA ...... sence of antihormonal therapy.
@nl
P2093
P1476
ERG status is unrelated to PSA ...... bsence of antihormonal therapy
@en
P2093
Alvin Y Liu
Andreas M Luebke
Antje Krohn
Carsten Bokemeyer
Guido Sauter
Hartmut Schlüter
Hüseyin Sirma
Jan C Brase
Julia Müller
Klaus Pantel
P304
P356
10.1158/1078-0432.CCR-11-1251
P407
P577
2011-07-26T00:00:00Z